Strategic Partnerships Orsini has a growing portfolio of high-profile partnerships with biopharma and device companies (Denali Therapeutics, Glaukos, Immedica, Dos Rx) and an integrated 3PL expansion. This presents cross-sell opportunities to align with manufacturers seeking exclusive specialty pharmacy access, expanded delivery models, and payer-agnostic distribution for rare disease therapies.

Rare Disease Focus As a leading independent specialty pharmacy for rare diseases and gene therapies, Orsini can be a preferred channel partner for manufacturers with niche, hard-to-reach patient populations, enabling therapy-specific care teams, adherence programs, and in-home infusion capabilities to differentiate drug launches.

Expansion Readiness National nursing coverage and in-home infusion services position Orsini to support nationwide rollouts and complex administration routes. This makes it a strong partner for introducing previously hospital-centers or clinic-managed therapies into home-based or community settings.

Digital and Data Capabilities With a tech stack including Power BI, AWS, HubSpot, and ORBIT Track, Orsini offers sophisticated analytics, marketing automation, and partner portal capabilities. This enables co-developed patient journey optimization, real-time performance dashboards, and scalable collaboration with manufacturers.

Resilience and Credentials ACHC and NABP accreditations along with a robust compliance posture, combined with a sizable revenue stream, create a trusted, scalable platform for engaging payers, patient support programs, and early-access initiatives for high-value rare-disease therapies.